Amnon Altman: Leading immunologist and educator retires
Dr. Altman’s research into T cell activation opened the door to new therapies for inflammation, autoimmune diseases, cancers, and more.
Cancer Immunology
In 2013, Dr. Vijayanand teamed up with Professor Christian Ottensmeier at the Cancer Center, University of Southampton, UK, to
A clue to how some fast-growing tumors hide in plain sight
New LJI research could guide the development of more effective cancer immunotherapies
Proteomics expert Sam Myers to join LJI faculty
Myers Lab to expand autoimmune disease research, cancer and more
Klaus Ley Receives $2.3 Million to Study Fundamentals of Immune Cell Activation
LA JOLLA—Scientists at La Jolla Institute for Immunology (LJI) have received a new grant of more than $2.3 million from the National
Targeting Tumor Endothelium for Cancer Surveillance and Immunotherapy
Preliminary data from our lab shows that vascular endothelial cells (vECs) mount remarkably potent innate responses to cell-free DNA, which
Cancer
Immunotherapies for head and neck cancer: To develop new cancer therapies by studying how the immune system, by way of
Sharma Lab
Sonia Sharma,
Ph.D.
Associate Professor
Center for Autoimmunity and Inflammation, Center for Cancer Immunotherapy
Sonia Sharma, Ph.D., and her lab members lead unbiased, genome-scale approaches to unravel innate immunity, the body’s early immune response to microbial pathogens and neoplastic cells.
Schoenberger Lab
Stephen Schoenberger,
Ph.D.
Professor
Center for Cancer Immunotherapy
Stephen Schoenberger, Ph.D., is focused on achieving a mechanistic understanding of the generation and regulation of T cell responses in the context of in vivo infection and tumor development.
LJI Scientists Investigate a Powerful Protein Behind Antibody Development
LA JOLLA, CA—Scientists at the La Jolla Institute for Immunology (LJI) have discovered a potential new way to better fight
LJI Donors Turn Health Crisis Into Mission to Champion Institute’s New Cancer Vaccine
Rebecca and Sandy Shapery embody that transformation, and they hope their inspirational journey will soon help save the lives of
Patient takes charge of his treatment path and partners with LJI researchers to create a fully personalized cancer vaccine
But Aldrich was not a normal patient. After the retired entrepreneur learned he had metastatic adenocarcinoma of the esophagus and